Objective To measure the effect on genital warts of the national human papillomavirus
vaccination programme in Australia, which started in mid-2007. Design Trend analysis of …

Background Australia has provided free quadrivalent human papillomavirus (HPV) vaccines
to school girls since mid-2007 and a catch-up programme in the community to women aged …

Objective: This study aimed to determine if the Australian human papillomavirus (HPV)
vaccination programme has had a population impact on presentations of genital warts …

Background Australia provided free quadrivalent human papillomavirus vaccines to 12–18-
year-old girls and women aged≤ 26 years from mid-2007 until the end of 2009. After this …

Background. Human papillomavirus (HPV) vaccination targeting females aged 12–13 years
commenced in Australia in 2007, with catch-up vaccination of females aged 13–26 years …

Background There has been a rapid decline in the number of young heterosexuals
diagnosed with genital warts at outpatient sexual health services since the national human …

Background Quadrivalent human papillomavirus (HPV) vaccine has high efficacy in clinical
trials but no reports describe its effects at a population level. From July, 2007, Australia was …

Objective To assess the cost effectiveness of routine vaccination of 12 year old schoolgirls
against human papillomavirus infection in the United Kingdom. Design Economic …

Background. More than 90% of genital warts (GW) cases are caused by human
papillomavirus (HPV) types 6 and 11. The introduction of HPV vaccines necessitates the …

Objective. To asses the burden and correlates of genital warts in women. Methods. We
conducted a population-based cross-sectional study in 69,147 women (18–45 years of age) …